THE SGLT2 INHIBITOR EMPAGLIFLOZIN CAUSES A GREATER REDUCTION IN SKIN SODIUM CONTENT AND INTERSTITIAL VOLUME THAN LOOP DIURETICS IN HEART FAILURE
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)31702-2
Abstract: The classic view that sodium (Na) in the extracellular volume (both intravascular and interstitial spaces) is in equilibrium has been recently challenged with the discovery of skin Na storage at higher concentrations than in blood.… read more here.
Keywords: volume; causes greater; sglt2 inhibitor; sodium ... See more keywords
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.827033
Abstract: The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and cardiovascular… read more here.
Keywords: male zucker; empagliflozin; zucker diabetic; inhibitor empagliflozin ... See more keywords